Articles about Alpine Immune Sciences

Vertex will buy Alpine Immune Sciences for $4.9B in another big Seattle biotech deal

Boston-based biotech company Vertex Pharmaceuticals agreed to acquire Seattle-based Alpine Immune Sciences for $65 per share, totaling about $4.9 billion… Read More

Tech Moves: Amazon promotes two execs to SVP; Providence exec named Teladoc COO; and more

— Amazon has promoted two executives to senior vice president: James Hamilton, a distinguished engineer at the company; and Drew… Read More

Life sciences and health tech news roundup: AIlen Institute’s new CEO, AI2’s incubator, and more

The legacy of the late Microsoft co-founder Paul Allen lives on at some of Seattle’s most innovative institutions. This week… Read More

Alpine raises $91M to fuel the Seattle biotech’s clinical trials for lupus and cancer

Alpine Immune Sciences will move a potential treatment for immune conditions into human testing and support its ongoing trials for… Read More

Alpine Immune Sciences stock rises after biotech firm lands $60M from AbbVie for lupus drug

Alpine Immune Sciences stock rose more than 10% Friday after the Seattle-based biotech company inked a $60 million licensing deal… Read More

Alpine Immune Sciences raising $17M in advance of merger with Colorado pharmaceutical company

Seattle biotech company Alpine Immune Sciences is raising $17 million as part of a merger with Nivalis, a publicly-traded pharmaceutical firm… Read More

Alpine Immune Sciences raises $48 million for cancer and autoimmune treatment

Seattle’s Alpine Immune Sciences says it has closed a $48 million Series A financing round, to fund the development of… Read More

Seattle’s Alpine Immune Sciences licenses cancer treatment to Kite Pharma for up to $530M

Seattle-based immunotherapy startup Alpine Immune Sciences has signed an exclusive licensing deal with Kite Pharma that could be worth as… Read More